#398 What's 340B? An Economist's View of the Recent Wave of 340B Litigation
The Federal 340B Drug Pricing Program has grown from a modest drug discount program into a massive federal program involving pharmaceutical manufacturers, hospitals, pharmacies, insurers, and third-party administrators. But when can similar conduct by participants in this program suggest coordination or raise other competition concerns? Archan Ruparel, economist at Charles River Associates, joins Brian Auricchio and Jaclyn Phillips to discuss economic considerations when evaluating potential antitrust concerns relating to 340B. Listen to this episode to learn more about factors that can help analyze this conduct. With special guest: Archan Ruparel, Charles River Associates Hosted by: Brian Auricchio, Haug Partners and Jaclyn Phillips, Proskauer Rose
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Our Curious Amalgam
#397 What's Next for the ABA Antitrust Law Section? Stability, Balance, and Value
#396 Is EU Law on Abuse of Dominance Now Clear? The ECJ's Judgment in Google Android
#395 Which Side of the V? Larry Buterman on Trying Antitrust Cases for the Government and Against It
#394 A Tribute to Randy Picker: Revisiting Episode #74 on the Implications of DOJ's Case Against IBM
Get summaries like this every morning.
Free AI-powered recaps of Our Curious Amalgam and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.